中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
6期
2397-2400
,共4页
结肠肿瘤%肿瘤转移%卡培他滨%奥沙利铂%阿司匹林%老年人
結腸腫瘤%腫瘤轉移%卡培他濱%奧沙利鉑%阿司匹林%老年人
결장종류%종류전이%잡배타빈%오사리박%아사필림%노년인
Colonic neoplasms%Neoplasm metastasis%Capecitabine%Oxaliplatin%Aspirin%Aged
目的探讨在转移性结肠癌中低剂量阿司匹林（ ASA ）与 Capox 方案联合时增效作用。方法选择54例无出血倾向的老年转移性结肠癌患者，随机分成2组：Capox方案组与Capox联合ASA组。28例Capox方案组病例单纯接受化疗：卡培他滨1000 mg·（m2）-1· d-1，d1～14，每日2次，口服，第1～14天；奥沙利铂130 mg/m2，静脉滴注，第1天。每3周为1周期。26例Capox联合ASA组接受化疗外，于化疗期及化疗间歇期均持续口服阿司匹林75 mg/d，同时口服奥美拉唑20 mg/d保护胃黏膜。结果（1） Capox＋ASA组与Capox组客观有效率（OR）无差异（57.6％ vs．46.4％，P＞0.05），但Capox ＋ASA 组疾病控制率（DCR）显著高于Capox组（92.3％vs．67.8％，P＜0.05）；（2）Capox＋ASA组1年、3年生存率均显著高于Ca-pox组（84.6％vs．67.8％；46.2％vs．28.6％，P均＜0.05）。（3）毒副反应包括神经毒性、白细胞减少、恶心呕吐与手足综合征等，四者发生率在Capox＋ASA组与Capox组无差异（ P＞0.05）。尽管两组手足综合征发生率无差别，但Capox＋ASA组有低发生率趋势（7.6％vs．14.3％），未观察到消化道出血副作用。结论 Capox联合低剂量ASA治疗老年转移性结肠癌患者，可延长生存期、降低毒副反应，具有“减毒增效”的作用。
目的探討在轉移性結腸癌中低劑量阿司匹林（ ASA ）與 Capox 方案聯閤時增效作用。方法選擇54例無齣血傾嚮的老年轉移性結腸癌患者，隨機分成2組：Capox方案組與Capox聯閤ASA組。28例Capox方案組病例單純接受化療：卡培他濱1000 mg·（m2）-1· d-1，d1～14，每日2次，口服，第1～14天；奧沙利鉑130 mg/m2，靜脈滴註，第1天。每3週為1週期。26例Capox聯閤ASA組接受化療外，于化療期及化療間歇期均持續口服阿司匹林75 mg/d，同時口服奧美拉唑20 mg/d保護胃黏膜。結果（1） Capox＋ASA組與Capox組客觀有效率（OR）無差異（57.6％ vs．46.4％，P＞0.05），但Capox ＋ASA 組疾病控製率（DCR）顯著高于Capox組（92.3％vs．67.8％，P＜0.05）；（2）Capox＋ASA組1年、3年生存率均顯著高于Ca-pox組（84.6％vs．67.8％；46.2％vs．28.6％，P均＜0.05）。（3）毒副反應包括神經毒性、白細胞減少、噁心嘔吐與手足綜閤徵等，四者髮生率在Capox＋ASA組與Capox組無差異（ P＞0.05）。儘管兩組手足綜閤徵髮生率無差彆，但Capox＋ASA組有低髮生率趨勢（7.6％vs．14.3％），未觀察到消化道齣血副作用。結論 Capox聯閤低劑量ASA治療老年轉移性結腸癌患者，可延長生存期、降低毒副反應，具有“減毒增效”的作用。
목적탐토재전이성결장암중저제량아사필림（ ASA ）여 Capox 방안연합시증효작용。방법선택54례무출혈경향적노년전이성결장암환자，수궤분성2조：Capox방안조여Capox연합ASA조。28례Capox방안조병례단순접수화료：잡배타빈1000 mg·（m2）-1· d-1，d1～14，매일2차，구복，제1～14천；오사리박130 mg/m2，정맥적주，제1천。매3주위1주기。26례Capox연합ASA조접수화료외，우화료기급화료간헐기균지속구복아사필림75 mg/d，동시구복오미랍서20 mg/d보호위점막。결과（1） Capox＋ASA조여Capox조객관유효솔（OR）무차이（57.6％ vs．46.4％，P＞0.05），단Capox ＋ASA 조질병공제솔（DCR）현저고우Capox조（92.3％vs．67.8％，P＜0.05）；（2）Capox＋ASA조1년、3년생존솔균현저고우Ca-pox조（84.6％vs．67.8％；46.2％vs．28.6％，P균＜0.05）。（3）독부반응포괄신경독성、백세포감소、악심구토여수족종합정등，사자발생솔재Capox＋ASA조여Capox조무차이（ P＞0.05）。진관량조수족종합정발생솔무차별，단Capox＋ASA조유저발생솔추세（7.6％vs．14.3％），미관찰도소화도출혈부작용。결론 Capox연합저제량ASA치료노년전이성결장암환자，가연장생존기、강저독부반응，구유“감독증효”적작용。
Objective To investigate the synergistic effect of aspirin in combined with Capox regimen in patients with metastatic colon cancer (mCRC).Methods 54 mCRC patients without haemorrhage tendency were divided randomly into two groups:the Capox regimen group received chemotherapy alone ( i.e capecitabine 1000 mg/m2 bid,d1-14;oxaliplatin,130 mg/m2 ,d1);the Capox regimen plus low-dose aspirin group receive chemotherapy and regular intake of aspirin(75 mg/d),together with oral administration of omeprazole (20 mg/d)against gastric mucosal injury.Results (1)No significant difference in overall response rate (OR)was observed between the Capox group and the combined group ( 57.6% vs.46.4% P >0.05 ) .Higher disease-control rate ( DCR ) was found in the combined group when compared with the Capox group (92.3%vs.67.8%,P<0.05).(2)The 1-and 3-year survival rates of patients with mCRC in the combined group were markedly higher than that in the Capox group respectively (84.6%vs.67.8%,46.2%vs.28.6%;P<0.05).(3)The common side-effects included neurotoxicity,leukocytes, nausea and vomiting ,and hand-foot syndrome ( HFS) .No statistical differences in the four side-effects existed between the two groups.However,the incidence of HFS in the combined group tended to decrease compared with the Capox group.No patients with mCRC in the combined group experienced the upper gastrointestinal bleeding . Conclusions The Capox regimen in combined with low-dose aspirin can prolong the survival in mCRC patients with lower incidence of HFS ,indicating the improved effect and decreased toxicity .
